
Novozymes A/S
- Jurisdiction
Denmark - LEI
529900T6WNZXD2R3JW38 - ISIN
DK0060336014 (NZYM-B.CO )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€73.34 34.4% undervalued - Financial strength (Piotroski F-Value)
-
7
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. Read full profile
Fundamentals
- Net revenue
€5.10B - Gross margin
54.8% - EBIT
€1.08B - EBIT margin
21.1% - Net income
€685.51M - Net margin
13.4%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
- Last dividend amount
-
DKK 4.20 - Ex date
-
- Payment date
-
- Dividend payout ratio
-
65.6%
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Earnings Calls
Latest earnings call: May 3, 2024 (Q1 2024)